Decheng Capital LLC
13F Reported Value
ⓘ$661.3M
Holdings
14
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Decheng Capital LLC disclosed 14 positions worth $661.3M in its Form 13F-HR for Q1 2026, led by $CGON (CG Oncology, Inc.) at 65.2% of the equity portfolio, followed by $NUVB and $UPB. During the quarter the fund opened 0 new positions and exited 4 and a full exit from $CRNX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Decheng Capital LLC’s Form 13F-HR filing with the SEC under CIK 2010850.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 28.0#2,455
Quality
$431.2M6,371,669 sh - 29.5#2,400
Quality
$111.3M25,954,439 sh - 22.6#2,633
Quality
$24.5M2,724,868 sh - 9.2
Quality
$15.2M4,041,736 sh - —
Quality
$14.8M3,917,299 sh - 3.6
Quality
$13.9M692,050 sh - —
Quality
$10.4M325,057 sh - 12.0
Quality
$10.3M477,819 sh - —
Quality
$9.1M93,500 sh - 27.2
Quality
$8.9M4,447,308 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 CG Oncology, Inc.$CGON | 28.0#2,455 | $431.2M | 6,371,669 |
 Nuvation Bio Inc.$NUVB | 29.5#2,400 | $111.3M | 25,954,439 |
 Upstream Bio, Inc.$UPB | 22.6#2,633 | $24.5M | 2,724,868 |
 Aclaris Therapeutics, Inc.$ACRS | 9.2 | $15.2M | 4,041,736 |
 Aardvark Therapeutics, Inc.$AARD | — | $14.8M | 3,917,299 |
 Lyell Immunopharma, Inc.$LYEL | 3.6 | $13.9M | 692,050 |
 NewAmsterdam Pharma Co N.V.$NAMS | — | $10.4M | 325,057 |
 Arcus Biosciences, Inc.$RCUS | 12.0 | $10.3M | 477,819 |
 Revolution Medicines, Inc.$RVMD | — | $9.1M | 93,500 |
 Equillium, Inc.$EQ | 27.2 | $8.9M | 4,447,308 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Decheng Capital LLC's 14 positions.
Showing top 10 of 14 holdings.
Sector Allocation
Healthcare
$661.3M
Full Holdings — Decheng Capital LLC (Q1 2026)
All 14 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $CGON | CG Oncology, Inc. | $431.2M | 65.2% | +0% | 28 |
| 2 | $NUVB | Nuvation Bio Inc. | $111.3M | 16.8% | +0% | 29.5 |
| 3 | $UPB | Upstream Bio, Inc. | $24.5M | 3.7% | -13% | 22.6 |
| 4 | $ACRS | Aclaris Therapeutics, Inc. | $15.2M | 2.3% | +0% | 9.2 |
| 5 | $AARD | Aardvark Therapeutics, Inc. | $14.8M | 2.2% | +0% | — |
| 6 | $LYEL | Lyell Immunopharma, Inc. | $13.9M | 2.1% | +0% | 3.6 |
| 7 | $NAMS | NewAmsterdam Pharma Co N.V. | $10.4M | 1.6% | -45% | — |
| 8 | $RCUS | Arcus Biosciences, Inc. | $10.3M | 1.6% | -12% | 12 |
| 9 | $RVMD | Revolution Medicines, Inc. | $9.1M | 1.4% | -53% | — |
| 10 | $EQ | Equillium, Inc. | $8.9M | 1.3% | +0% | 27.2 |
| 11 |  $BYSI | BeyondSpring Inc. | $6.2M | 0.9% | +0% | — |
| 12 |  $ZNTL | Zentalis Pharmaceuticals, Inc. | $3.1M | 0.5% | +0% | — |
| 13 |  $KRYS | Krystal Biotech, Inc. | $1.9M | 0.3% | -58% | 75.9 |
| 14 |  $PYXS | Pyxis Oncology, Inc. | $477,143 | 0.1% | +0% | — |
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Decheng Capital LLC including:
Track Decheng Capital LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Decheng Capital LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Decheng Capital LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Decheng Capital LLC (SEC CIK: 2010850), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Decheng Capital LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.